For patients with metastatic colorectal cancer, treatment often involves more than traditional chemotherapy. In select cases, doctors recommend targeted therapies that interfere with cancer cell growth at the molecular level. One of the most studied and prescribed of these is Erbitux for colorectal cancer, a monoclonal antibody designed to target EGFR (epidermal growth factor receptor).

For patients diagnosed with esophageal cancer, particularly at an advanced or unresectable stage, immunotherapy has become an important area of clinical focus. One of the newer treatment combinations involves Opdivo Qvantig for esophageal cancer, a regimen that may offer a survival benefit over traditional chemotherapy alone in certain patients.

Breast cancer is a growing concern. Explore its causes, crucial US statistics, and modern approaches to detection and treatment for a hopeful future.

Leukemia treatment continues to evolve with the development of more targeted therapies, offering patients new hope when standard treatments no longer work. One of the latest additions to this landscape is Imkeldi for leukemia, a medication recently introduced for individuals with relapsed or refractory acute myeloid leukemia (AML).

For men diagnosed with advanced or metastatic prostate cancer, hormone therapies are often part of the long-term treatment plan. One option that continues to be widely used is Abiraterone for prostate cancer, a medication that helps slow tumor growth by reducing androgen levels—the hormones that fuel prostate cancer cells.